Correct, the MHRA explicitly approved the trial design and the fda also likely approved the design. Any bullshit about issues with the trial design is just that, bullshit.
I think Ray Tancredi would disagree with you. He has served as the divisional vice president at Walgreens for well over a decade and has studied the clinical pipeline to FDA approval for years.
Mr. Tancredi compiled an interesting list of pipeline drugs to watch in 2023. His list and commentary were recently published in the news section of the website for The American Journal of Managed Care®: